Research Topics
Species | J A SloanSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Genetic variations and patient-reported quality of life among patients with lung cancerJeff A Sloan
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 30:1699-704. 2012..We report an analysis exploring relationships among baseline QOL assessments and candidate genetic variations in a large cohort of patients with lung cancer...
Relationship between deficits in overall quality of life and non-small-cell lung cancer survivalJeff A Sloan
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 30:1498-504. 2012..This study evaluated the prognostic value of QOL assessments with regard to OS in a large cohort of patients with lung cancer...
Responsiveness and minimal important differences for patient reported outcomesDennis A Revicki
Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814, USA
Health Qual Life Outcomes 4:70. 2006..Responsiveness and MID must be demonstrated and documented for the particular study population, and these measurement characteristics are needed for PRO labeling and promotional claims...
Development and preliminary psychometric properties of a well-being index for medical studentsLiselotte N Dyrbye
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
BMC Med Educ 10:8. 2010....
Towards the prevention of acute lung injury: a population based cohort study protocolSweta J Thakur
Multidisciplinary Epidemiology and Translational Research in Intensive Care, Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
BMC Emerg Med 10:8. 2010..Olmsted County, MN, geographically isolated from other urban areas offers the opportunity to study clinical pathogenesis of ALI in a search for potential prevention targets...
Limited sampling models for CPT-11, SN-38, and SN-38 glucuronideJ A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Cancer Chemother Pharmacol 48:241-9. 2001..We developed limited sampling models (LSMs) for predicting the area under the curve (AUC) of irinotecan (CPT-11) and its metabolites SN-38 and SN-38 glucuronide (SN-38G)...
Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networksJeff A Sloan
Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 25:5070-7. 2007..There remains a need for more research in several methodologic aspects of design, analysis, and interpretation of symptom management trials...
Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trialsJ A Sloan
Department of Health Sciences Research, Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA
J Biopharm Stat 14:73-96. 2004..We populate the paper with concrete examples of how QOL data need not be treated any different, in terms of statistical analysis, than tumor response or other clinical end points...
Metrics to assess quality of life after management of early-stage lung cancerJeff A Sloan
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Cancer J 17:63-7. 2011..The primary conclusion from this work is that scientifically sound investigations into the QOL of early-stage lung cancer patients are feasible and encouraged so that the care of these patients can be optimized...
A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1)Jeff A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 52:371-81. 2002....
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancerJeff A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:1491-8. 2002..After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken...
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plotJeff A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Qual Life Res 11:37-45. 2002..We explore alternative options to customize the graphic representation for other data sets drawn from several NCCTG clinical trials...
The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomesJeff A Sloan
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Value Health 10:S59-63. 2007..This is vitally important because after all, at the heart of all healthcare endeavors is the patient...
A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain indexJ A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 19:3539-46. 2001..The objective was to produce a simple, practical, stratification factor for phase III oncology clinical trials involving patients with advanced malignant disease...
Assessing the minimally clinically significant difference: scientific considerations, challenges and solutionsJeff A Sloan
Mayo Clinic Rochester, Cancer Center Statistics, 200 1st St SW, Rochester, Minnesota 55905, USA
COPD 2:57-62. 2005..4. A process of MCID estimation involving all approaches to produce a potential range with sensitivity analyses is the optimal solution to producing an MCID based on the most complete knowledge possible...
Patients with reconstruction of craniofacial or intraoral defects: development of instruments to measure quality of lifeJ A Sloan
Mayo Medical School, Rochester, Minnesota, USA
Int J Oral Maxillofac Implants 16:225-45. 2001..The instruments were used with equal success both in face-to-face interviews and via mail...
Analysis and interpretation of results based on patient-reported outcomesJeff A Sloan
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Value Health 10:S106-15. 2007..g.,missing data, multiplicity, null results etc.). The manuscript provides key literature for existing resources and proposes new guidelines...
The clinical significance of quality of life assessments in oncology: a summary for cliniciansJeff A Sloan
Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Support Care Cancer 14:988-98. 2006..The theoretical discussion is supplemented with an example of how the various ideas can be operationalized in an oncology clinical trial...
Sex differences in fluorouracil-induced stomatitisJ A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 18:412-20. 2000....
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activityA A Adjei
Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
J Clin Oncol 18:1116-23. 2000....
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumorsA A Adjei
Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 18:1748-57. 2000..Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase I trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy...
Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosisAdam Svobodnik
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 79:1024-30. 2004..To present the results of a quality-of-life (QOL) assessment performed with the current version of the Lung Cancer Symptom Scale (LCSS) questionnaire in a large single-institutional data set of 650 patients with lung cancer...
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivorsC L Loprinzi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 16:2377-81. 1998..Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem...
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566C Erlichman
Mayo Clinic Cancer Center, Rochester, Minnesota, USA
Ann Oncol 12:389-95. 2001..We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity...
Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapyTimothy F Kozelsky
Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
J Clin Oncol 21:1669-74. 2003..99). The maximum number of stools per day was 5.1 for the glutamine arm and 5.2 for the placebo arm (P =.99). CONCLUSION: There is no evidence of a beneficial effect of glutamine during pelvic RT...
A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatinJulian R Molina
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Anticancer Drugs 16:997-1002. 2005..However, the combination of BAY, VP-16 and CDBCA produces significant hematologic toxicity. Findings from this study may help to direct further studies with other inhibitors of MMPs...
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trialC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Lancet 356:2059-63. 2000..We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer...
Lack of effect of coumarin in women with lymphedema after treatment for breast cancerC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
N Engl J Med 340:346-50. 1999..Coumarin has been reported to be effective for the treatment of women with lymphedema; we undertook a study in which we attempted to replicate those findings...
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexiaC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 17:3299-306. 1999..The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia...
Burnout and suicidal ideation among U.S. medical studentsLiselotte N Dyrbye
Mayo Clinic, Rochester, Minnesota, USA
Ann Intern Med 149:334-41. 2008..Little is known about the prevalence of suicidal ideation among U.S. medical students or how it relates to burnout...
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1Barbara A Pockaj
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 24:2836-41. 2006..CONCLUSION: This trial failed to provide any evidence that black cohosh reduced hot flashes more than the placebo...
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathyJulie E Hammack
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Pain 98:195-203. 2002..Cross-validation sensitivity analysis of results support the conclusion that nortriptyline provides modest improvement at best over placebo in terms of chemotherapy-related neuropathy...
Levetiracetam for the treatment of hot flashes: a phase II studySusan Thompson
Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
Support Care Cancer 16:75-82. 2008..The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors...
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorinR M Goldberg
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Ann Oncol 13:1674-80. 2002..This combination can be administered safely to this schedule if there is strict adherence to the 90 min infusion time for both CPT-11 and 5-FU...
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activityA A Adjei
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 60:1871-7. 2000..i.d.) but also provides the first evidence of successful inhibition of FT in the clinical setting and the first hint of clinical activity for this class of agents...
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumorsGrace K Dy
Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Cancer Chemother Pharmacol 55:522-30. 2005..Eight patients had disease stabilization for five or more cycles. CONCLUSION: Gemcitabine immediately followed by pemetrexed is well tolerated and clinically active, and deserves further evaluation in phase II trials...
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot studyThomas M Habermann
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 84:795-8. 2009..The use of potential agents of risk by the survivors and the lack of access to potentially beneficial modalities highlights the need for further study of CAM in this population...
A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survivalPaul D Brown
Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Neurosurgery 57:495-504; discussion 495-504. 2005..001), and greater extent of resection (P < 0.001). CONCLUSION: Baseline QOL was predictive of QOL over time. Gross total resection was associated with longer survival and improved QOL over time for patients with high-grade gliomas...
A pessimistic explanatory style is prognostic for poor lung cancer survivalPaul Novotny
Cancer Center Statistics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
J Thorac Oncol 5:326-32. 2010..Having a pessimistic outlook has been related to negative health behaviors and higher mortality. However, the construct has not been well explored in cancer populations...
Tamoxifen-induced hot flashesC L Loprinzi
Mayo Clinic, Mayo Foundation, Rochester, MN, USA
Clin Breast Cancer 1:52-6. 2000....
Methodologic lessons learned from hot flash studiesJ A Sloan
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 19:4280-90. 2001..CONCLUSION: Given the data gained from these experiences, we can plan and carry out more efficient trials to identify efficacious agents for the reduction of hot flash activity...
Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancerC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 15:969-73. 1997..The present trial was developed to evaluate the nonhormonal vaginal lubricating preparation, Replens, for alleviating these symptoms...
Complementary and alternative medicine use by patients enrolled onto phase I clinical trialsGrace K Dy
Division of Medical Oncology, Department of Medicine, Mayo Foundation and Mayo Clinic College of Medicine, Rochester, MN, USA
J Clin Oncol 22:4810-5. 2004..CONCLUSION: CAM use is common among patients in phase I trials and should be ascertained by investigators, because some of the agents used may interact with investigational agents and affect adverse effects and/or efficacy...
North Central Cancer Treatment Group--achievements and perspectivesAxel Grothey
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Semin Oncol 35:530-44. 2008....
On appetite and its lossAminah Jatoi
Division of Medical Oncology and Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:79s-81s. 2003
Lung cancer screening with CT: Mayo Clinic experienceStephen J Swensen
Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Radiology 226:756-61. 2003..Six hundred ninety-six additional findings of clinical importance were identified. CONCLUSION: CT can depict early-stage lung cancers. The rate of benign nodule detection is high...
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri
Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leukemia 19:118-25. 2005..Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study...
Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patientsDona E C Locke
Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, Arizona 85259, USA
J Pain Symptom Manage 34:628-38. 2007..The data suggest that the single-item LASA scales are valid for assessing QOL of cancer patients and are an appropriate alternative when a shorter instrument is warranted...
Association of resident fatigue and distress with perceived medical errorsColin P West
Division of General Internal Medicine, Department of Medicine, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
JAMA 302:1294-300. 2009..Fatigue and distress have been separately shown to be associated with medical errors. The contribution of each factor when assessed simultaneously is unknown...
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patientsRuben A Mesa
Department of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 109:68-76. 2007..Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD)...
Measuring spiritual quality of life in patients with cancerMary E Johnson
Department of Chaplain Services, Mayo Clinic, Rochester, MN 55905, USA
J Support Oncol 5:437-42. 2007....
Meeting on the FDA draft guidance on patient-reported outcomesAmylou C Dueck
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Value Health 10:S64-5. 2007
How do distress and well-being relate to medical student empathy? A multicenter studyMatthew R Thomas
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Gen Intern Med 22:177-83. 2007....
The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)Debra L Barton
Mayo Clinic Rochester, Rochester, MN 55905, USA
J Support Oncol 9:24-31. 2011..However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with valerian exploring physiologic effects in oncology symptom management may be warranted...
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 112:1772-9. 2008....
Motivational readiness for physical activity and quality of life in long-term lung cancer survivorsMatthew M Clark
Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
Lung Cancer 61:117-22. 2008..Physical activity level may have important QOL and symptom management benefits for long-term lung cancer survivors...
Burnout and serious thoughts of dropping out of medical school: a multi-institutional studyLiselotte N Dyrbye
Mayo Clinic, Department of Medicine, Rochester, Minnesota, USA
Acad Med 85:94-102. 2010..The authors assessed the severity of thoughts of dropping out and explored the relationship of such thoughts with burnout and other indicators of distress...
Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based studyPing Yang
College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Thorac Oncol 4:479-85. 2009....
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9Debra L Barton
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 28:3278-83. 2010..Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief...
Therapeutic exercise during outpatient radiation therapy for advanced cancer: Feasibility and impact on physical well-beingAndrea L Cheville
Departments of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA
Am J Phys Med Rehabil 89:611-9. 2010..To characterize the feasibility of delivering a structured physical therapy (PT) program as part of a multidisciplinary intervention to patients undergoing outpatient radiation therapy for advanced cancer...
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CCStephanie L Hines
Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
Breast Cancer Res Treat 117:603-9. 2009..Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen...
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancerStephanie L Hines
Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 27:1047-53. 2009..Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer...
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1Charles L Loprinzi
Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
J Clin Oncol 29:1472-8. 2011..The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated...
Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CAJames A Martenson
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 26:5248-53. 2008..To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy...
The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemiaTait D Shanafelt
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
Leuk Res 33:263-70. 2009..The effectiveness with which physicians help patients adjust to the physical, intellectual, and emotional challenges of CLL appears to impact patient QOL...
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)Aminah Jatoi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 113:847-53. 2008..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3Ravi D Rao
Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 112:2802-8. 2008..Based on such data, a multicenter double-blind, placebo-controlled, randomized trial was conducted to evaluate the effect of lamotrigine on pain and other neuropathic symptoms due to chemotherapy-induced peripheral neuropathy (CIPN)...
Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experienceCharles L Loprinzi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Menopause 15:655-60. 2008..This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group...
The learning environment and medical student burnout: a multicentre studyLiselotte N Dyrbye
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Med Educ 43:274-82. 2009..The authors conducted a comprehensive assessment of how learning environment, clinical rotation factors, workload, demographics and personal life events relate to student burnout...
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapyStephanie L Hines
Mayo Clinic Florida, Jacksonville, FL 32224, USA
Breast 19:92-6. 2010..Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole...
Quality of life of caregivers of patients with advanced-stage cancerMatthew M Clark
Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
Am J Hosp Palliat Care 23:185-91. 2006..Further investigation is warranted in this area, including interventions specifically designed and targeted to both reduce caregiver burden and to improve caregiver QOL...
Genetic determinants of lung cancer short-term survival: the role of glutathione-related genesPing Yang
Department of Health Sciences Research, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Lung Cancer 35:221-9. 2002..We tested the hypothesis that genes encoding glutathione enzymes may predict lung cancer short-term survival...
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumorsHenry C Pitot
Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Clin Cancer Res 8:712-7. 2002..To evaluate the toxicities, characterize the pharmacokinetics, and determine the maximum-tolerated dose of bizelesin administered once every 4 weeks...
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7Charles L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 24:1409-14. 2006..This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes...
Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?Paul Brown
Department of Oncology, Mayo Clinic Rochester, Rochester, MN 55905, USA
Am J Clin Oncol 29:52-8. 2006..In this project, we examined the impact that participation in a randomized controlled trial of a multidisciplinary intervention designed to impact overall QOL had on fatigue for advanced cancer patients actively receiving treatment...
Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trialTeresa A Rummans
Department of Psychiatry and Psychology, Mayo Clinic Cancer Center, and Medical Social Services, Mayo Clinic, Rochester MN 55905, USA
J Clin Oncol 24:635-42. 2006....
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemiaScott H Kaufmann
Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
Clin Cancer Res 11:6641-9. 2005..To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias...
Pilot evaluation of gabapentin for treating hot flashesL Loprinzi
Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:1159-63. 2002..To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes...
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effortAminah Jatoi
Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 22:2469-76. 2004..This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA...
Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathyElizabeth A Bradley
Department of Ophthalmology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Ophthalmology 113:1450-4. 2006..To determine the potential suitability of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) for measuring health-related quality of life (HRQL) in patients with Graves' ophthalmopathy...
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancerAlex A Adjei
Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 9:2520-6. 2003..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
Association of perceived medical errors with resident distress and empathy: a prospective longitudinal studyColin P West
Division of General Internal Medicine, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
JAMA 296:1071-8. 2006..Medical errors are associated with feelings of distress in physicians, but little is known about the magnitude and direction of these associations...
Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablationMatthew R Callstrom
Department of Radiology, Mayo Clinic, 200 First St SW, E2, Rochester, MN 55905, USA
Radiology 224:87-97. 2002..Eight of 10 patients using analgesics reported reduced use at some time after RF ablation. No serious complications were observed. CONCLUSION: RF ablation of painful osteolytic metastases is safe, and the relief of pain is substantial...
Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysisMatthew R Callstrom
Department of Diagnostic Radiology, Oncology, Biostatistics, and Anesthesiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Radiology 241:572-80. 2006....
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigationAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Support Care Cancer 10:71-5. 2002..Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss...
Phase III evaluation of fluoxetine for treatment of hot flashesCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:1578-83. 2002..Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed...
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomasE Galanis
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Gene Ther 12:437-45. 2005..There was evidence of antitumor activity in one out of six patients. Further investigation of this approach in patients with recurrent sarcomas is warranted...
Overall survival and self-reported fatigue in patients with esophageal cancerM C Stauder
Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
Support Care Cancer 21:511-9. 2013..A prospective cohort study was conducted to analyze whether self-reported fatigue predicts overall survival in patients with esophageal cancer...
Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastasesP M Anderson
Department of Pediatrics, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 5:2316-23. 1999..Aerosol delivery of GM-CSF is feasible, safe, and possibly effective. Aerosol cytokine delivery may achieve effective immunological activation against cancer in the lung and is worthy of further study...
Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigationA Jatoi
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Cancer 92:629-33. 2001..Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated...
Quality of Life endpoints in prostate chemoprevention trialsJ A Sloan
Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
Urology 57:235-40. 2001..As such, great care needs to be given to a priori determination of the QOL constructs that are most likely to change...
Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized settingGary A Croghan
Mayo Clinic and Mayo Foundation Rochester MN 55905, USA
Nicotine Tob Res 5:181-7. 2003..Combination nicotine nasal spray and nicotine patches were delivered safely in a nonspecialized outpatient clinical setting and enhanced short-term smoking abstinence rates, but these rates were not sustained at 6 months...
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinomaAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 97:1442-6. 2003..This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma...
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:4574-80. 2002..To evaluate quality of life (QOL) and tumor response after administration of an oral chemotherapy regimen in patients with previously untreated metastatic colorectal cancer...
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States
Leuk Res 32:691-8. 2008..Within the limitations of self-reported data, these results provide a benchmark for future interventions to improve QOL in patients with MDS...
The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancerClaudette G Varricchio
J Natl Cancer Inst 94:1184-5. 2002
Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of termsJeff A Sloan
Department of Health Sciences Research, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:367-70. 2002..A secondary goal is to stimulate further discussion and research in the interpretation of QOL assessments...
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphomaStephen M Ansell
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 99:67-74. 2002..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group studyAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:567-73. 2002..To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia...
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancersPaul L Schaefer
Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, USA
Am J Clin Oncol 26:236-40. 2003..Topotecan showed significant activity in the treatment of extensive stage SCLC when administered as a brief daily IV repeated every 3 weeks...
Mapping the journey of cancer patients through health care system. Part 1: developing the research questionJeff A Sloan
Faculty of Nursing, University of Manitoba
Can Oncol Nurs J 14:183-6, 188-91. 2004..A large interdisciplinary team collaborated on developing operational methods to combine existing data sources into unified cancer patient histories...
